1. Introduction {#sec1}
===============

Antimicrobials have been widely used in veterinary medicine as therapeutic or prophylactic agents. However, the use of such medications may result in the presence of their residues in eggs, which may cause allergic reactions or toxicity or lead to the selection of antibiotic-resistant microorganisms in humans \[[@B1]\]. Because of the ovarian follicle development and of preovulatory hierarchy, many weeks may be required following treatment or exposure before eggs are free of some drug residues \[[@B2]\].

To ensure food safety, study and determination of the appropriate withdrawal period of antimicrobials used in the treatment of the hens as well as an efficient residue control in food products from animal origin are essential. Maximum residue limits (MRL) for veterinary drug residues in foods of animal origin were established by European Regulation number 37/2010 and the Codex Alimentarius Commission, based on the acceptable daily intake (ADI) of each drug and considering maximum food intake \[[@B3]--[@B5]\]. Nevertheless, to ensure compliance with these regulations, sensitive and specific analytical methods, capable of monitoring quickly and efficiently the presence and the level of these residues, are necessary \[[@B6], [@B7]\].

The analytical methods for determination of veterinary drugs residues in foods may be classified as screening or as quantitative and confirmatory methods. Microbiological inhibitory plate test methods may be used for the screening of antimicrobial residues. However, due to the presence of inhibitory substances, especially in the albumen, which serve as natural defense against microbial contamination and proliferation, the eggs are not considered a common product to be tested by microbiological inhibitory tests. Furthermore, these methods are not sensitive enough and not really specific; therefore a further postscreening step is necessary in order to determine the identity of the previously detected inhibitory substance \[[@B8]\]. Screening methods that employ ultra-performance liquid chromatography coupled to tandem mass spectrometry (UHPLC-MS/MS) techniques may be used as a semiquantitative postscreening tool, providing the unambiguous identification of the analytes of interest and the information about the compliance of the analyzed samples with the MRL established by regulatory agencies or a specific level of interest \[[@B9]\].

Despite the number of papers available in the literature about the development and validation of analytical methods for study of veterinary drug residues in foods of animal origin, there are few articles about the determination of antimicrobial residues in eggs by UHPLC-MS/MS, due to the complexity of the egg matrix. The papers available in the literature do not evaluate some classes of substances, such as the aminoglycosides \[[@B7], [@B10]--[@B14]\]. Furthermore, some of the developed methodologies are not validated \[[@B7], [@B12]\] or have recoveries for some analytes outside of the recommended limits for validation \[[@B11]\]. According to the EURACHEM \[[@B15]\], when the matrix used in the validated methodology changes, a new validation should be performed, since a standard method can not be used outside the scope for which it was designed. Moreover, most published studies that have evaluated the withdrawal period of antimicrobials in laying hens used microbiological assays \[[@B16]--[@B18]\] or other techniques, such as high-performance liquid chromatography (HPLC) or HPLC-mass spectrometry \[[@B19]--[@B23]\]. Thus, there is a lack of papers in the scientific literature on the elimination of these residues in eggs by UHPLC-MS/MS, as well as the evaluation of the compliance or not of the egg samples from laying hens subjected to a pharmacological treatment in relation to the MRL established by regulatory agencies.

Thus, the purpose of this work was to optimize and validate a qualitative and confirmatory method for screening of antimicrobials from tetracyclines, aminoglycosides, quinolones, lincosamides, *β*-lactams, sulfonamides, and macrolides families in eggs by UHPLC-MS/MS and evaluate its application as a semiquantitative screening method for detection of antimicrobial residues in eggs from hens that had been subjected to a pharmacological treatment.

2. Materials and Methods {#sec2}
========================

2.1. Chemicals and Reagents {#sec2.1}
---------------------------

The analytical standards used for the tetracyclines (chlortetracycline, doxycycline, oxytetracycline, and tetracycline) and aminoglycosides (amikacin, apramycin, dihydrostreptomycin, gentamicin, hygromycin, kanamycin, neomycin, spectinomycin, streptomycin, and tobramycin) families were purchased from Sigma Chemical Co. (St. Louis, MO, USA). For the quinolones family, the standards of enrofloxacin, flumequine, norfloxacin, oxolinic acid, and sarafloxacin were obtained from Sigma Chemical Co., whereas the ciprofloxacin and the nalidixic acid were purchased from the Acros Organics (Geel, Belgium) and from the CDN Isotopes (Quebec, Canada), respectively. The standard of lincomycin, from the lincosamides family, as well as the standards from the macrolides (clindamycin, erythromycin, spiramycin, tilmicosin, and tylosin) and *β*-lactams (cefazolin, cloxacillin, dicloxacillin, oxacillin, nafcillin, penicillin G, and penicillin V) families were purchased from Sigma Chemical Co. For the sulfonamides family, the standards of sulfachloropyridazine, sulfadiazine, sulfadimethoxine, sulfadoxine, sulfamerazine, sulfamethazine, sulfamethoxazole, sulfamethoxypyridazine, sulfaquinoxaline, sulfathiazole, and sulfisoxazole were obtained from Sigma Chemical Co., whereas the standards of sulfadiazine and sulfathiazole were obtained from Dr. Ehrenstorfer Standards (Augsburg, Germany). All reagents used were of pro analysis (p.a.) grade, except the solvents used in UHPLC, which were of HPLC grade.

2.2. Standard Solutions {#sec2.2}
-----------------------

The purchased antimicrobial standards were used for the preparation of individual standard stock solutions in methanol or water, depending on the solubility of each antimicrobial at concentrations of 200 *μ*g mL^−1^ (tetracyclines, *β*-lactams, and aminoglycosides), 1000 *μ*g mL^−1^ (quinolones and sulfonamides), and 100 *μ*g mL^−1^ (lincomycin and macrolides).

Two working mixed standard solutions were prepared. The first, used in the extraction procedure by trichloroacetic acid (TCA), was diluted with ultrapure water (0.1 *μ*g mL^−1^ for quinolones, 4 *μ*g mL^−1^ for tetracyclines, 0.5 *μ*g mL^−1^ for lincosamides, and 5 *μ*g mL^−1^ for the aminoglycosides) and remained stable for 30 days when stored at −20°C. The second working mixed standard solution, used in the extraction procedure by acetonitrile, was also prepared in ultrapure water (0.1 *μ*g mL^−1^ for sulfonamides, 0.5 *μ*g mL^−1^ for *β*-lactams, and 1.5 *μ*g mL^−1^ for the macrolides, except for tylosin that was prepared at a concentration of 2.0 *μ*g mL^−1^) and remained stable for one week when stored at −20°C. All standard solutions were stored protected from light in amber bottles.

2.3. Sample Preparation {#sec2.3}
-----------------------

The internal content of the eggs (albumen and yolk) was homogenized using Ultra Turrax (IKA®, Wilmington, NC, USA) and then 2.0 g of samples was weighed in 50 mL polypropylene centrifuge tubes. Then, two extractions procedures, adapted from Gaugain-Juhel et al. \[[@B8]\], followed by two acquisition methods were employed to allow the screening of all 45 studied antimicrobials.

2.4. Extraction of Tetracyclines, Aminoglycosides, Quinolones, and Lincosamides {#sec2.4}
-------------------------------------------------------------------------------

The analytes were extracted from 2 g egg samples with 8 mL of 5% TCA solution. The tubes were mixed for 10 minutes in an orbital shaker. Then, 1.5 mL of the obtained extract was transferred to centrifuge microtubes and centrifuged (14.462 ×g), at 4°C, for 12 minutes in a refrigerated centrifuge (SIGMA 3-30KS®, ATR, Laurel, MD, USA). After centrifugation, the supernatant was filtered through a filter unit with polytetrafluoroethylene (PTFE) membrane (pore size of 0.22 *μ*m, diameter 13 mm, FilterPro®) and the filtrate was transferred to a vial for injection. The extraction procedure was adapted from the method described by Gaugain-Juhel et al. \[[@B8]\].

2.5. Extraction of Macrolides, *β*-Lactams, and Sulfonamides {#sec2.5}
------------------------------------------------------------

The samples were added to 8 mL of acetonitrile, stirred for 10 min, and then centrifuged at 3000 ×g at 4°C, for 10 minutes in a refrigerated centrifuge (SIGMA 3-30KS, ATR). The supernatant (6 mL) was evaporated under nitrogen flow at 40 ± 3°C and the obtained extract was dissolved in 0.6 mL of 0.2 M ammonium acetate solution and filtered through a filter unit with PTFE membrane (pore size of 0.22 *μ*m, diameter 13 mm, FilterPro) and the filtrate was transferred to a vial insert for injection. The method of extraction was adapted from Gaugain-Juhel et al. \[[@B8]\].

2.6. Instrumentation {#sec2.6}
--------------------

Chromatographic separation was performed in an UHPLC system (Prominence Shimadzu), using an Agilent Zorbax Eclipse XDB C18 3.5 *μ*m × 4.6 × 30 mm, with a vanguard column. The gradient mixing 0.2% heptafluorobutyric acid (HFBA) (mobile phase A) and acetonitrile (mobile phase B) was used for the separation of the tetracyclines, aminoglycosides, quinolones, and lincosamides. Initial conditions were set at 10% B with a linear gradient from 10% B to 50% from 0.01 to 7 minutes, and then 50% B was held for 4 min with an immediate return to 10% B at 12 min. The total run time for each injection was 13 min. The gradient optimized for the separation of macrolides, *β*-lactams, and sulfonamides, mixing 0.1% HFBA (mobile phase A) and acetonitrile (mobile phase B), started with 10% B. It was then increased linearly to 30% of B over 4 min and then stopped for 1 min at 30% and again raised linearly to 70% of B over 3 min and stopped for 3 min at 70%. The initial composition was then recovered over a 5-min delay. The total run time was 16 min. The flow rate was set at 0.6 mL min^−1^ and the partial loop with needle overfills injection volume was 20 *μ*L in both cases.

For the detection and identification of the targeted analytes, a 4000 QTRAP® triple quadrupole mass detector was used (AB Sciex, Darmstadt, Germany), set in positive ESI mode. The capillary voltage was set at 5.5 kV and the temperature of the source at 650°C. Declustering potential (DP) and the collision energy (CE) were optimized for each analyte by infusing solutions of the antimicrobial standards prepared in the mobile phase, in order to improve the signal intensity. Nitrogen was used as collision gas at 8.0 psi and curtain gas at 20.0 psi. Two MRM transitions were established and monitored for each analyte. The major transition (1st transition) was used for analyte identification and the minor transition (2nd transition) for their confirmation. The presence of two MRM transitions with a signal-to-noise ratio (S/N) \> 3 in combination with the expected retention time guarantees the univocal identification of the analyte.

2.7. Validation Procedure {#sec2.7}
-------------------------

The UHPLC-MS/MS method was validated by referencing the validation procedure to monitor antimicrobial residues in milk described by Gaugain-Juhel et al. \[[@B8]\]. According to these authors, the proposed scheme of validation, applied to an UHPLC-MS/MS postscreening method, is more suitable than the classical approach of validation usually applied to quantitative methods that check parameters, such as trueness, precision, and linearity. The evaluation of many samples at the level of interest, assessing statistically the capacity of detection of the method, was considered more relevant, because the aim of a validation is to prove the suitability of the method in achieving the goal for which it is developed. Generally, the level of interest corresponds to the MRL level and the samples are spiked at this concentration for the validation. However, for some compounds, for which MRL is established for the parent drug plus its metabolite or for different compounds (e.g., tetracyclines), a level of interest lower than the MRL, such as 0.75 MRL, may be chosen \[[@B3], [@B5], [@B8]\]. Thus, the validation procedure was performed at different levels of interest, according to the MRL established for each drug ([Table 1](#tab1){ref-type="table"}).

The parameters evaluated in this work were selectivity \[[@B6]\], *T*-value, cut-off factor (Fc), limit of detection (LOD), detection capability (CC*β*), and sensitivity \[[@B8], [@B24]\].

The selectivity of the method was evaluated by analyses of 20 blank samples, from different batches, and from laying hens that were not treated with antimicrobials, to check the presence of any interferences (signals, peaks, and ion traces) in the region of interest, which elute at the same retention time as the target analytes \[[@B6]\].

The calculation of the *T*-value for each compound of interest is a first step in assessing the capacity of detection. *T*-value is a "threshold" value corresponding to the minimum analytical response above which the sample will be truly considered as positive. This parameter was determined by analyses of 20 blank samples from different origins and calculated using the equation: *T*-value = *B* + 1.64 × SD~*B*~, which considers the mean value of the noise "*B*" and the standard deviation of 20 recorded noises "SD~B~" \[[@B8]\].

The LOD was calculated using the equation: LOD = 3*B* × *C*/*M*~an~, which considers the mean noise "*B*," a known concentration of the studied analytes "*C*," and the mean response of 20 samples spiked at a known concentration "*M*~an~" \[[@B8]\].

The Fc was determined by analyses of 20 blank samples spiked at the level of interest for each analyte, within the same day. This step was repeated again twice. The repetitions were carried out on three different days (*n* = 60). The analytical response was determined for the samples and for the two MRM transitions from each analytes, and the Fc was calculated using the following equation: Fc = *M*~an~ − 1.64 × SD~an~, which considers the mean response from the 60 samples "*M*~an~" and the standard deviation "SD" for each analyte (*n* = 60) and for two MRM transitions \[[@B8]\].

The detection capability (CC*β*) was evaluated by a comparison of the *T*-value and Fc. The *T*-value and Fc values obtained can lead to different situations: the first is when Fc \> *T*-value, corresponding to the best situation, with a false-negative rate below 5%; in this case, the CC*β* is truly below the MRL level. However, when Fc \< *T*-value, if the *T*-value is taken as a limit of positivity, more than 5% of the samples will be considered as negative. The consequence is that the CC*β* is truly above the MRL level \[[@B8]\].

The sensitivity of the method was determined by analyses of 20 blank samples, spiked at the level of interest, and compared with the Fc. The number of true positive samples giving a positive test result, also called "positive agreement", was divided by the number of true positive samples and expressed as a percentage \[[@B8]\].

2.8. Applicability Demonstration by Animal Experiment Study {#sec2.8}
-----------------------------------------------------------

For the evaluation of applicability of the validated method, 600 Hy-Line W36 laying hens, with 40 weeks of age, were used. The birds were housed in production cages with ad libitum access to water and feed. The hens were randomly allocated into six experimental groups, labeled from A to F, containing 100 birds each. Hens from the A group formed the untreated control group and received nonmedicated feed throughout the experimental period, whereas those from groups B, C, D, E, and F received medicated feed containing neomycin, enrofloxacin, lincomycin, oxytetracycline, and doxycycline, respectively, during 5 days.

Before the initiation of treatment, 6 repetitions with a pool of 10 eggs each were collected from each group. Then, additional 6 repetitions of 10 eggs each were daily collected of all experimental groups, during the period of 15 days (5 days of treatment with medicated feed and 10 days of discontinuation of the medication). The samples were individually identified and sent to laboratory for UHPLC-MS/MS analyses using the previously validated method.

This study was carried out in strict accordance with the recommendations of the National Council for the Control of Animal Experimentation (CONCEA) at the Brazilian Ministry of Science and Technology and Innovation (MCTI). The protocol was approved by the Ethics Committee in Animal Experimentation at the*Universidade Federal de Minas Gerais* (UFMG) (Permit Number: 400/2015).

3. Results and Discussion {#sec3}
=========================

3.1. Mass Spectrometry Optimization {#sec3.1}
-----------------------------------

The operational conditions of the mass spectrometer were established by a direct infusion of the standards. The MRM transitions, monitored for each analyte, the declustering potential (DP), and the collision energy (CE) were optimized in order to improve the signal intensity. The relative ion intensity was evaluated according to the criteria established by European Commission Decision 2002/675/EC \[[@B6]\] and proved to be adequate for all the analytes (Tables [2](#tab2){ref-type="table"} and [3](#tab3){ref-type="table"}).

3.2. Validation Study {#sec3.2}
---------------------

According to the selectivity evaluation, the blank samples did not present interferences in the region of the studied analytes and signal suppression/enhancement by the egg matrix was not observed which compromised the detection of the analytes, except for the flumequine, which was eluted in the same retention time of the an interferent compound from the TCA 5% solution ([Figure 1](#fig1){ref-type="fig"}). This interferent compound provided a signal enhancement in the transition 262 \> 244.

The detection capability (CC*β*) was evaluated by a comparison of the *T*-value and Fc. When Fc \> *T*-value, the CC*β* is truly below the MRL level, indicating a false-negative rate below 5%. However, when Fc \< *T*-value, if the *T*-value is taken as a limit of positivity, more than 5% of the samples will be considered as negative. The consequence is that the CC*β* is truly above the MRL level. The results obtained for the two transitions at validation concentration (*C*~val~) were satisfactory for all the studied analytes, except for the flumequine, where Fc was lower than the *T*-value in transition 1 and consequently the CC*β* was higher than the level of interest (Tables [4](#tab4){ref-type="table"} and [5](#tab5){ref-type="table"}). This result may be justified due to the presence of an interferent compound that was eluted in the same retention time of this analyte.

The recommendation of the European Commission Decision 2002/675/EC \[[@B6]\] for screening methods is that they had the capability of a high sample throughput and allow the detection of the analytes of interest with a false-compliant rate below 5% at the level of interest; therefore the CC*β* of the method should be found below this level of interest. In the case of a suspected noncompliant result, this result should be confirmed by a confirmatory method.

The LOD of the method, for the analytes extracted with TCA, showed minimum values lower than 1 *μ*g kg^−1^ and the maximum values of 7.60 *μ*g kg^−1^. The highest LOD values were found for the analytes from the aminoglycosides family, followed by the antimicrobials from the tetracyclines family ([Table 4](#tab4){ref-type="table"}). For the analytes extracted with acetonitrile, the minimum values obtained for the antimicrobials from the *β*-lactams family were lower than 1 *μ*g kg^−1^ with the maximum of 2.98 *μ*g kg^−1^, whereas, for the sulfonamides and macrolides families, the LOD was lower than 1 *μ*g kg^−1^ for all studied analytes ([Table 5](#tab5){ref-type="table"}).

The sensitivity was 100% for the first transition of all analytes extracted by TCA, except for spectinomycin, which had a sensitivity of 95%. For the second transition, the sensitivity found was 100% for all analytes of these groups, with the exception of apramycin and dihydrostreptomycin, wherein the sensitivity was 95% ([Table 4](#tab4){ref-type="table"}). For all the analytes extracted by acetonitrile, the sensitivity was 100% ([Table 5](#tab5){ref-type="table"}). A sensitivity above 95% means that the CC*β* is below the level of concentration tested for validation; therefore the number of false-negatives is truly below 5% \[[@B8]\].

3.3. Applicability of the Method {#sec3.3}
--------------------------------

The applicability of the method was evaluated by analyses of egg samples from hens that had been subjected to pharmacological treatment with the antimicrobials neomycin, enrofloxacin, lincomycin, oxytetracycline, and doxycycline administered via feed. Egg samples were classified as compliant or noncompliant by comparing their instrumental responses with the responses obtained in the analyzes of samples spiked at 0.75 times the validation concentration of each drug ([Table 1](#tab1){ref-type="table"}), defined as positive control. Residues of neomycin, enrofloxacin and its metabolite ciprofloxacin, lincomycin, oxytetracycline, and doxycycline were not detected in any of the egg samples of hens from control group, indicating that there was no contamination of the feed and no cross-contamination during the treatments.

Residues of neomycin were not detected, during all the experimental period, in the egg samples from hens treated with neomycin. This drug has effective action in the gastrointestinal tract and is poorly absorbed from normal gastrointestinal tract and probably could not reach, in eggs, detectable concentrations by validated method.

In the egg samples from hens treated with enrofloxacin, a rapid increase in the levels of enrofloxacin residues was observed after initiation of drug administration. Residue concentrations of the drug that were higher than the reference limit (positive control) of 7.5 *μ*g kg^−1^ were found in the egg samples until nine days after the end of treatment. Ciprofloxacin showed similar characteristics; however, residue concentrations higher than the reference limit (positive control) were found up to six days after the discontinuation of the treatment ([Figure 2](#fig2){ref-type="fig"}); these results were expected, because ciprofloxacin is a metabolite of enrofloxacin.

The physiology of egg production is directly related to the accumulation of antimicrobial residues in eggs after laying. In the ovary of a laying hen, several follicles at varying developmental stages are present simultaneously. Before the laying of an egg, the yolk undergoes a phase of rapid growth, in which it increases in size exponentially over 10 days \[[@B25]\]. Hence, antimicrobials that deposit preferentially in the yolk will rapidly accumulate during this time and can be present in successive eggs for 10 or more days following treatment. Following maturation, the yolk moves to the magnum region of the oviduct and the majority of the albumen is deposited from secreted proteins, over a 2-3 h period, and may also serve as a residue accumulation site \[[@B2], [@B26]\]. Physicochemical properties of the drugs, such as its tendency to bind to plasma proteins, hydrophobicity, or hydrophilicity, also influence the distribution and persistence of residues in eggs and many drugs may deposit preferentially in the yolk or albumen according to those characteristics \[[@B27]\].

After oral administration, fluoroquinolones are rapidly absorbed, with high bioavailability \[[@B28]--[@B30]\], extensive metabolism, and distribution to tissues \[[@B29]--[@B31]\]. Although there is no general agreement regarding fluoroquinolone distribution, some authors described that these drugs accumulate mainly in the yolk \[[@B32], [@B33]\]. As the yolk has a long development time, which depends on a preovulatory hierarchy, residues of fluoroquinolones can be incorporated into this matrix, especially when the yolk undergoes a phase of rapid growth, in which it increases in size exponentially over 10 days due to incorporation of lipoproteins secreted in the liver \[[@B2], [@B25]\]. This may justify the long period of permanence of enrofloxacin residues in eggs after cessation of treatment, being detected in the egg samples, at concentrations higher than the reference limit (positive control) until nine days after the end of treatment.

In the group of hens treated with lincomycin, the highest concentrations of the drug were found during the treatment period. When the treatment was discontinued at the 5th day, the concentrations of lincomycin declined rapidly and were present in concentrations higher than the reference limit (positive control) of 37.5 *μ*g kg^−1^ up to one day after the discontinuation of the treatment ([Figure 3](#fig3){ref-type="fig"}).

Lincosamides are antimicrobials that have basic nature and high affinity for plasma proteins \[[@B34]\]. As the albumen is formed in the magnum region of the oviduct from secreted plasmatic proteins, generally formed on the previous day of posture \[[@B35], [@B36]\], the residue level of lincomycin probably rapidly reduces due to this property.

In contrast with the results observed for lincomycin, residues of oxytetracycline were below the reference limit (positive control) of 225 *μ*g kg^−1^ during all the experimental period ([Figure 4](#fig4){ref-type="fig"}).

Oxytetracycline is the least lipophilic member of the tetracycline group and consequently has a lower rate of absorption after oral administration, which may explain the observed results \[[@B34]\].

However, in the group of hens treated with doxycycline, residues of the drug were found at concentrations higher than the reference limit (positive control) of 225 *μ*g kg^−1^ up to four days after the discontinuation of the treatment ([Figure 5](#fig5){ref-type="fig"}).

Doxycycline is the most lipophilic of the tetracyclines and consequently has a high absorption and distribution \[[@B37]\]. According to literature data, after administration, residues of doxycycline increase rapidly and the concentrations found in egg white are much higher during treatment and 1 day after withdrawal. However, the levels in albumen decrease rapidly, whereas the concentrations reach higher levels and persist longer in egg yolk \[[@B38]\].

4. Conclusion {#sec4}
=============

The results demonstrated the applicability of the proposed method that may be used in routine analysis as a qualitative or as a semiquantitative tool in order to identify the analyte present in the samples and direct it to analysis for a quantitative and confirmatory method, thereby reducing the costs of analyses. The evaluation of the eggs after antimicrobial administration to laying hens demonstrated the absence of neomycin, during all experimental period, and the presence of enrofloxacin, ciprofloxacin, lincomycin, and doxycycline at concentrations higher than the positive control level for each drug. Residues of oxytetracycline were found, but at low concentrations during all the experimental period.
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![Chromatogram of a method blank-extraction with 5% trichloroacetic acid, without the addition of the egg matrix (a), to demonstrate the presence of an interferent compound from the TCA 5% solution and chromatogram of the egg matrix with the addition of the standard solutions of tetracyclines, aminoglycosides, quinolones, and lincosamides at the 0.75 MRL level (b).](JAMC2017-3259073.001){#fig1}

![Residues of enrofloxacin and ciprofloxacin in egg samples from layer hens subjected to a pharmacological treatment with enrofloxacin, during the drugs administration period and days of residual evaluation.](JAMC2017-3259073.002){#fig2}

![Residues of lincomycin in egg samples from layer hens subjected to a pharmacological treatment with lincomycin, during the drug administration period and days of residual evaluation.](JAMC2017-3259073.003){#fig3}

![Residues of oxytetracycline in egg samples from layer hens subjected to a pharmacological treatment with oxytetracycline during the drug administration period and days of residual evaluation.](JAMC2017-3259073.004){#fig4}

![Residues of doxycycline in egg samples from layer hens subjected to a pharmacological treatment with doxycycline during the drug administration period and days of residual evaluation.](JAMC2017-3259073.005){#fig5}

###### 

Level of interest for individual analytes, according to the Codex Alimentarius^4^ and European Union^3^ MRL, for the method validation.

  -----------------------------------------------------------------------------------------------------------------------------
  Analytes                                    MRL (*μ*g kg^−1^)                          Validation concentration (*C*~val~)\
                                                                                         (*μ*g kg^−1^)
  ------------------------------------------- ------------------------------------------ --------------------------------------
  *Tetracyclines*                                                                         

   Chlortetracycline + epichlortetracycline   400^a^                                     300

   Doxycycline                                Not established^a^                         300^c^

   Oxytetracycline + epioxytetracycline       400^a^                                     300

   Tetracycline + epitetracycline             400^a^                                     300

  *Aminoglycosides*                                                                       

   Amikacin                                   Not established^b^                         500^c^

   Apramycin                                  Banned from being used in laying hens^b^   500^c^

   Dihydrostreptomycin                        No MRL in eggs^b^                          500^c^

   Gentamicin                                 No MRL in eggs^b^                          500^c^

   Hygromycin                                 Not established^b^                         500^c^

   Kanamicin                                  Banned from being used in laying hens^b^   500^c^

   Neomycin                                   500^b^                                     500

   Spectinomycin                              Banned from being used in laying hens^b^   500^c^

   Streptomycin                               No MRL in eggs^b^                          500^c^

   Tobramycin                                 Not established^b^                         500^c^

  *Quinolones*                                                                            

   Ciprofloxacin                              Banned from being used in laying hens^b^   10

   Enrofloxacin                               Banned from being used in laying hens^b^   10

   Flumequine                                 Banned from being used in laying hens^b^   10

   Nalidixic acid                             Not established^b^                         10

   Norfloxacin                                Not established^b^                         10

   Oxolinic acid                              Banned from being used in laying hens^b^   10

   Sarafloxacin                               Banned from being used in laying hens^b^   10

  *Lincosamides*                                                                          

   Lincomycin                                 50^b^                                      50

  *β-Lactams*                                                                             

   Cefazolin                                  No MRL in eggs^b^                          50

   Cloxacillin                                Banned from being used in laying hens^b^   50

   Dicloxacillin                              Banned from being used in laying hens^b^   50

   Nafcillin                                  No MRL in eggs^b^                          50

   Oxacillin                                  Banned from being used in laying hens^b^   50

   Penicillin G                               Banned from being used in laying hens^b^   50

   Penicillin V                               Not established^b^                         50

  *Sulfonamides*                                                                          

   Sulfachloropyridazine                      Banned from being used in laying hens^b^   10

   Sulfadiazine                               Banned from being used in laying hens^b^   10

   Sulfadimethoxine                           Banned from being used in laying hens^b^   10

   Sulfadoxine                                Banned from being used in laying hens^b^   10

   Sulfamerazine                              Banned from being used in laying hens^b^   10

   Sulfamethazine                             Banned from being used in laying hens^b^   10

   Sulfamethoxazole                           Banned from being used in laying hens^b^   10

   Sulfamethoxypyridazine                     Banned from being used in laying hens^b^   10

   Sulfaquinoxaline                           Banned from being used in laying hens^b^   10

   Sulfathiazole                              Banned from being used in laying hens^b^   10

   Sulfisoxazole                              Banned from being used in laying hens^b^   10

  *Macrolides*                                                                            

   Clindamycin                                Not established^b^                         150

   Erythromycin                               Not established^b^                         150

   Spiramycin                                 Banned from being used in laying hens^b^   150

   Tilmicosin                                 Banned from being used in laying hens^b^   150

   Tylosin                                    200^b^                                     200
  -----------------------------------------------------------------------------------------------------------------------------

^a^Codex Alimentarius Commission^4^; ^b^European Regulation number 37/2010^3^; ^c^for the analytes banned from being used in laying hens or those analytes that did not have an established MRL, the method was used only as a qualitative screening method.

###### 

MRM transitions and MS/MS parameters for tetracyclines, aminoglycosides, quinolones, and lincosamides after optimization, in the trichloroacetic acid extract.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Analytes               DP^a^ \   Major transition\   CE^b^ \   Minor transition 1 (*m/z*)   CE^b^ \   Minor transition 2\   CE^b^ \   RT^c^ \   Relative intensity
                         (V)       (*m*/*z*)           (eV)                                   (eV)      (*m*/*z*)             (eV)      (min)     
  ---------------------- --------- ------------------- --------- ---------------------------- --------- --------------------- --------- --------- --------------------
  *Tetracyclines*                                                                                                                                  

   Chlortetracycline     61        479/98              67        479/275                      55        ---                   ---       6.0       84.4 ± 5.0

   Doxycycline           55        445/428             25        445/154                      40        ---                   ---       6.3       5.8 ± 0.6

   Oxytetracycline       41        461/201             59        461/283                      53        ---                   ---       4.9       50.1 ± 4.1

   Tetracycline          55        445/410             27        445/427                      25        ---                   ---       5.2       25.9 ± 2.1

  *Aminoglycosides*                                                                                                                                

   Amikacin              60        586/425             21        586/163                      53        ---                   ---       4.8       374.9 ± 52.7

   Apramycin             82        540/217             35        540/378                      25        ---                   ---       5.2       112.6 ± 13.3

   Dihydrostreptomycin   120       584/263             42        584/246                      54        584/409               4         4.3       33.1 ± 3.2

   Gentamicin            50        478/157             25        464/322                      20        464/160               20        5.5       132.5 ± 20.1

   Hygromycin            50        528/177             25        528/352                      25        ---                   ---       4.2       207.4 ± 19.9

   Kanamycin             70        485/163             35        485/205                      35        ---                   ---       4.8       45.5 ± 5.7

   Neomycin              120       615/161             41        615/296                      35        ---                   ---       5.9       25.9 ± 2.7

   Spectinomycin         66        351/207             31        351/189                      33        ---                   ---       3.6       52.1 ± 2.6

   Streptomycin          157       582/263             45        582/246                      51        582/407               54        4.3       55.1 ± 7.4

   Tobramycin            50        468/163             20        468/324                      55        ---                   ---       5.3       7.4 ± 2.0

  *Quinolones*                                                                                                                                     

   Ciprofloxacin         61        332/314             30        332/231                      47        ---                   ---       4.8       79.9 ± 12.1

   Enrofloxacin          72        360/342             30        360/286                      50        ---                   ---       5.2       28.2 ± 5.2

   Flumequine            44        262/244             25        262/202                      45        ---                   ---       7.0       9.6 ± 1.5

   Nalidixic acid        42        233/215             30        233/187                      35        ---                   ---       6.8       96.2 ± 2.9

   Norfloxacin           60        320/302             33        320/231                      50        ---                   ---       4.7       26.9 ± 4.2

   Oxolinic acid         53        262/244             25        262/216                      40        ---                   ---       5.4       17.1 ± 1.6

   Sarafloxacin          50        386/368             30        386/348                      40        ---                   ---       5.6       5.8 ± 2.2

  *Lincosamides*                                                                                                                                   

   Lincomycin            60        407/126             40        407/359                      26        ---                   ---       4.3       8.2 ± 0.7
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^DP: declustering potential; ^b^CE: collision energy; ^c^RT: retention time.

###### 

MRM transitions and MS/MS parameters for *β*-lactams, sulfonamides, and macrolides after optimization, in the acetonitrile acid extract.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Analytes                  DP^a^ \   Major transition\   CE^b^ \   Minor transition 1\   CE^b^ \   Minor transition 2\   CE^b^ \   RT^c^ \   Relative intensity
                            (V)       (*m/z*)             (eV)      (*m/z*)               (eV)      (*m/z*)               (eV)      (min)     
  ------------------------- --------- ------------------- --------- --------------------- --------- --------------------- --------- --------- --------------------
  *β-lactams*                                                                                                                                  

   Cefazolin                50        455/323             15        455/156               23        ---                   ---       4.1       53.6 ± 3.3

   Cloxacillin              50        436/160             20        436/277               20        ---                   ---       8.3       120.5 ± 7.2

   Dicloxacillin            50        470/160             20        470/311               20        ---                   ---       8.6       65.9 ± 4.2

   Nafcillin                50        415/199             20        415/171               50        ---                   ---       8.4       31.4 ± 0.9

   Oxacillin                50        402/160             18        402/243               18        ---                   ---       8.0       105.4 ± 9.3

   Penicillin G             70        335/176             21        335/160               21        335/114               37        7.3       103.7 ± 11.2

   Penicillin V             66        351/160             15        351/192               17        ---                   ---       7.7       9.9 ± 3.1

  *Sulfonamides*                                                                                                                               

   Sulfachloropyridazine    51        285/156             21        285/92                39        ---                   ---       4.6       39.4 ± 1.8

   Sulfadiazine             53        251/156             22        251/108               30        ---                   ---       2.6       39.2 ± 3.4

   Sulfadimethoxine         50        311/156             23        311/108               37        ---                   ---       6.1       30.8 ± 1.5

   Sulfadoxine              60        311/156             25        311/108               40        ---                   ---       5.0       30.8 ± 1.5

   Sulfamerazine            60        265/92              35        265/156               35        ---                   ---       3.1       44.6 ± 3.0

   Sulfamethazine           50        279/156             25        279/108               36        ---                   ---       3.6       76.8 ± 3.2

   Sulfamethoxazole         60        254/108             35        254/92                35        ---                   ---       5.0       117.3 ± 9.5

   Sulfamethoxypyridazine   60        281/156             25        281/108               35        ---                   ---       4.0       40.7 ± 2.0

   Sulfaquinoxaline         50        301/156             23        301/108               40        ---                   ---       6.2       33.6 ± 1.3

   Sulfathiazole            53        256/156             20        256/108               34        ---                   ---       3.1       33.6 ± 1.5

   Sulfisoxazole            46        268/156             21        268/113               23        ---                   ---       5.4       59.8 ± 5.0

  *Macrolides*                                                                                                                                 

   Clindamycin              75        425/126             43        425/377               27        ---                   ---       6.9       8.9 ± 0.3

   Erythromycin             66        734/158             43        734/576               27        ---                   ---       7.6       50.3 ± 2.0

   Spiramycin               56        422/174             31        422/101               25        ---                   ---       7.4       65.7 ± 8.4

   Tilmicosin               56        869/174             63        869/696               57        ---                   ---       7.8       61.1 ± 3.4

   Tylosin                  115       916/174             55        916/772               43        ---                   ---       7.8       35.1 ± 1.4
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^DP: declustering potential; ^b^CE: collision energy; ^c^RT: retention time.

###### 

Results of the method validation for tetracyclines, aminoglycosides, quinolones, and lincosamides families.

  Analytes               Transition 1 "major"   Transition 2 "minor"                                                        
  ---------------------- ---------------------- ---------------------- ------- ------- ----------- ----------------- ------ -----
  *Tetracyclines*                                                                                                            
   Chlortetracycline     Fc \> *T*              *\<C* ~val~ ^d^        \<1     100     Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Doxycycline           Fc \> *T*              *\<C* ~val~ ^d^        \<1     100     Fc \> *T*   *\<C* ~val~ ^d^   7.36   100
   Oxytetracycline       Fc \> *T*              *\<C* ~val~ ^d^        \<1     100     Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Tetracycline          Fc \> *T*              *\<C* ~val~ ^d^        \<1     100     Fc \> *T*   *\<C* ~val~ ^d^   1.08   100
  *Aminoglycosides*                                                                                                          
   Amikacin              Fc \> *T*              *\<C* ~val~ ^d^        3.71    100     Fc \> *T*   *\<C* ~val~ ^d^   3.29   100
   Apramycin             Fc \> *T*              *\<C* ~val~ ^d^        7.60    100     Fc \> *T*   *\<C* ~val~ ^d^   5.22   95
   Dihydrostreptomycin   Fc \> *T*              *\<C* ~val~ ^d^        \<1     100     Fc \> *T*   *\<C* ~val~ ^d^   \<1    95
   Gentamicin            Fc \> *T*              *\<C* ~val~ ^d^        4.68    100     Fc \> *T*   *\<C* ~val~ ^d^   5.44   100
   Hygromycin            Fc \> *T*              *\<C* ~val~ ^d^        \<1     100     Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Kanamycin             Fc \> *T*              *\<C* ~val~ ^d^        \<1     100     Fc \> *T*   *\<C* ~val~ ^d^   4.87   100
   Neomycin              Fc \> *T*              *\<C* ~val~ ^d^        6.22    100     Fc \> *T*   *\<C* ~val~ ^d^   6.91   100
   Spectinomycin         Fc \> *T*              *\<C* ~val~ ^d^        \<1     95      Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Streptomycin          Fc \> *T*              *\<C* ~val~ ^d^        \<1     100     Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Tobramycin            Fc \> *T*              *\<C* ~val~ ^d^        5.18    100     Fc \> *T*   *\<C* ~val~ ^d^   7.01   100
  *Quinolones*                                                                                                               
   Ciprofloxacin         Fc \> *T*              *\<C* ~val~ ^d^        \<1     100     Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Enrofloxacin          Fc \> *T*              *\<C* ~val~ ^d^        \<1     100     Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   *Flumequine*          *Fc \<T*               *\>C* ~*val*~ ^*d*^    *\<1*   *100*   Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Lincomycin            Fc \> *T*              *\<C* ~val~ ^d^        \<1     100     Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Nalidixic acid        Fc \> *T*              *\<C* ~val~ ^d^        \<1     100     Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Norfloxacin           Fc \> *T*              *\<C* ~val~ ^d^        \<1     100     Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Oxolinic acid         Fc \> *T*              *\<C* ~val~ ^d^        \<1     100     Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Sarafloxacin          Fc \> *T*              *\<C* ~val~ ^d^        \<1     100     Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
  *Lincosamides*                                                                                                             
   Lincomycin            Fc \> *T*              *\<C* ~val~ ^d^        \<1     100     Fc \> *T*   *\<C* ~val~ ^d^   \<1    100

^a^Fc: cut-off factor; ^b^LOD: limit of detection; ^c^Sens: sensitivity of the method; ^d^*C*~val~: level of interest for each analyte according to [Table 1](#tab1){ref-type="table"}.

###### 

Results of the method validation for *β*-lactams, sulfonamides, and macrolides families.

  Analytes                  Transition 1 "major"   Transition 2 "minor"                                                    
  ------------------------- ---------------------- ---------------------- ----- ----- ----------- ----------------- ------ -----
  *β-lactams*                                                                                                               
   Cefazolin                Fc \> *T*              *\<C* ~val~ ^d^        \<1   100   Fc \> *T*   *\<C* ~val~ ^d^   2.98   100
   Cloxacillin              Fc \> *T*              *\<C* ~val~ ^d^        \<1   100   Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Dicloxacillin            Fc \> *T*              *\<C* ~val~ ^d^        \<1   100   Fc \> *T*   *\<C* ~val~ ^d^   2.10   100
   Nafcillin                Fc \> *T*              *\<C* ~val~ ^d^        \<1   100   Fc \> *T*   *\<C* ~val~ ^d^   2.35   100
   Oxacillin                Fc \> *T*              *\<C* ~val~ ^d^        \<1   100   Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Penicillin G             Fc \> *T*              *\<C* ~val~ ^d^        \<1   100   Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Penicillin V             Fc \> *T*              *\<C* ~val~ ^d^        \<1   100   Fc \> *T*   *\<C* ~val~ ^d^   1.76   100
  *Sulfonamides*                                                                                                            
   Sulfachloropyridazine    Fc \> *T*              *\<C* ~val~ ^d^        \<1   100   Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Sulfadiazine             Fc \> *T*              *\<C* ~val~ ^d^        \<1   100   Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Sulfadimethoxine         Fc \> *T*              *\<C* ~val~ ^d^        \<1   100   Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Sulfadoxine              Fc \> *T*              *\<C* ~val~ ^d^        \<1   100   Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Sulfamerazine            Fc \> *T*              *\<C* ~val~ ^d^        \<1   100   Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Sulfamethazine           Fc \> *T*              *\<C* ~val~ ^d^        \<1   100   Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Sulfamethoxazole         Fc \> *T*              *\<C* ~val~ ^d^        \<1   100   Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Sulfamethoxypyridazine   Fc \> *T*              *\<C* ~val~ ^d^        \<1   100   Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Sulfaquinoxaline         Fc \> *T*              *\<C* ~val~ ^d^        \<1   100   Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Sulfathiazole            Fc \> *T*              *\<C* ~val~ ^d^        \<1   100   Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Sulfisoxazole            Fc \> *T*              *\<C* ~val~ ^d^        \<1   100   Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
  *Macrolides*                                                                                                              
   Clindamycin              Fc \> *T*              *\<C* ~val~ ^d^        \<1   100   Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Erythromycin             Fc \> *T*              *\<C* ~val~ ^d^        \<1   100   Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Spiramycin               Fc \> *T*              *\<C* ~val~ ^d^        \<1   100   Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Tilmicosin               Fc \> *T*              *\<C* ~val~ ^d^        \<1   100   Fc \> *T*   *\<C* ~val~ ^d^   \<1    100
   Tylosin                  Fc \> *T*              *\<C* ~val~ ^d^        \<1   100   Fc \> *T*   *\<C* ~val~ ^d^   \<1    100

^a^Fc: cut-off factor; ^b^LOD: limit of detection; ^c^Sens: sensitivity of the method; ^d^*C*~val~: level of interest for each analyte according to [Table 1](#tab1){ref-type="table"}.

[^1]: Academic Editor: Luca Campone
